JP2003520822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520822A5 JP2003520822A5 JP2001554694A JP2001554694A JP2003520822A5 JP 2003520822 A5 JP2003520822 A5 JP 2003520822A5 JP 2001554694 A JP2001554694 A JP 2001554694A JP 2001554694 A JP2001554694 A JP 2001554694A JP 2003520822 A5 JP2003520822 A5 JP 2003520822A5
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- type
- diabetes
- pancreas
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003053 toxin Substances 0.000 description 20
- 108030001720 Bontoxilysin Proteins 0.000 description 13
- 229940053031 botulinum toxin Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- NGNQZCDZXSOVQU-UHFFFAOYSA-N 8,16,18,26,34,36-hexahydroxyhentetracontane-2,6,10,14,24,28,32-heptone Chemical compound CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCCCC(O)CC(O)CC(=O)CCCC(=O)CC(O)CC(=O)CCCC(C)=O NGNQZCDZXSOVQU-UHFFFAOYSA-N 0.000 description 3
- 101000939689 Araneus ventricosus U2-aranetoxin-Av1a Proteins 0.000 description 3
- 101000633673 Buthacus arenicola Beta-insect depressant toxin BaIT2 Proteins 0.000 description 3
- 101000654318 Centruroides noxius Beta-mammal toxin Cn2 Proteins 0.000 description 3
- 101001028695 Chironex fleckeri Toxin CfTX-2 Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 3
- 229940094657 botulinum toxin type a Drugs 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000331 sympathetic ganglia Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108010069022 botulinum toxin type D Proteins 0.000 description 1
- 108010069023 botulinum toxin type E Proteins 0.000 description 1
- 108010069038 botulinum toxin type F Proteins 0.000 description 1
- 108010069071 botulinum toxin type G Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000035860 hypoinsulinemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/491,420 US6337075B1 (en) | 2000-01-11 | 2000-01-26 | Methods for treating diabetes |
| US09/491,420 | 2000-01-26 | ||
| PCT/US2001/002273 WO2001054711A2 (en) | 2000-01-26 | 2001-01-24 | Use of neurotoxins for treating diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520822A JP2003520822A (ja) | 2003-07-08 |
| JP2003520822A5 true JP2003520822A5 (https=) | 2008-03-13 |
| JP4851042B2 JP4851042B2 (ja) | 2012-01-11 |
Family
ID=23952146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554694A Expired - Lifetime JP4851042B2 (ja) | 2000-01-26 | 2001-01-24 | 糖尿病の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6337075B1 (https=) |
| EP (1) | EP1250146B1 (https=) |
| JP (1) | JP4851042B2 (https=) |
| AR (1) | AR029464A1 (https=) |
| AT (1) | ATE257013T1 (https=) |
| AU (1) | AU2001231104A1 (https=) |
| DE (1) | DE60101669T2 (https=) |
| DK (1) | DK1250146T3 (https=) |
| ES (1) | ES2211765T3 (https=) |
| TW (1) | TWI233806B (https=) |
| WO (1) | WO2001054711A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| ATE519494T1 (de) * | 2000-02-08 | 2011-08-15 | Allergan Inc | Pharmazeutische zusammensetzungen mit botulinum- toxin |
| US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US6486127B1 (en) * | 2001-05-23 | 2002-11-26 | Insmed, Incorporated | Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof |
| US6492339B1 (en) * | 2001-05-23 | 2002-12-10 | Insmed, Incorporated | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof |
| US6984375B2 (en) * | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| WO2003047589A1 (en) * | 2001-11-15 | 2003-06-12 | Micro Algae Corporation | Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| WO2005110417A1 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
| JP2007538010A (ja) * | 2004-05-07 | 2007-12-27 | ファイトトックス リミテッド | フィコトキシンの経皮投与 |
| US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| WO2006130161A2 (en) * | 2004-07-21 | 2006-12-07 | The Cornell Research Foundation, Inc. | Therapeutic compounds derived from spider venom and their method of use |
| EP1982997B1 (en) | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| EP1871789B1 (en) | 2005-03-15 | 2013-11-06 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| WO2009002437A2 (en) * | 2007-06-25 | 2008-12-31 | The Board Of Regents Of The University Of Texas System | Neurotoxin theraphy for postprandial hyperglycemia |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| FR2972928B1 (fr) * | 2011-03-25 | 2013-11-29 | Urgo Lab | Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement |
| US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
| GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| CN107108703B (zh) | 2015-01-09 | 2022-09-23 | 益普生生物创新有限公司 | 阳离子神经毒素 |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| WO2019162696A1 (en) | 2018-02-26 | 2019-08-29 | Ipsen Biopharm Limited | Use of ultrasound to guide injection of non-cytotoxic protease |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| KR102520631B1 (ko) | 2019-10-18 | 2023-04-12 | 펜랜드 파운데이션 | 치료에 사용하기 위한 보톨리늄 독소 |
| US11925677B2 (en) * | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| WO2021231666A1 (en) | 2020-05-15 | 2021-11-18 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US20220143158A1 (en) * | 2020-09-18 | 2022-05-12 | Vanderbilt University | Duodenal administration of botulinum toxin |
| GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
| WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| ES2332905T3 (es) | 1993-12-28 | 2010-02-15 | Allergan, Inc. | Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos. |
| US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| DE69627963T2 (de) | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
-
2000
- 2000-01-26 US US09/491,420 patent/US6337075B1/en not_active Expired - Fee Related
-
2001
- 2001-01-19 TW TW090101295A patent/TWI233806B/zh not_active IP Right Cessation
- 2001-01-24 DE DE60101669T patent/DE60101669T2/de not_active Expired - Lifetime
- 2001-01-24 WO PCT/US2001/002273 patent/WO2001054711A2/en not_active Ceased
- 2001-01-24 ES ES01903262T patent/ES2211765T3/es not_active Expired - Lifetime
- 2001-01-24 JP JP2001554694A patent/JP4851042B2/ja not_active Expired - Lifetime
- 2001-01-24 AU AU2001231104A patent/AU2001231104A1/en not_active Abandoned
- 2001-01-24 EP EP01903262A patent/EP1250146B1/en not_active Expired - Lifetime
- 2001-01-24 AT AT01903262T patent/ATE257013T1/de not_active IP Right Cessation
- 2001-01-24 DK DK01903262T patent/DK1250146T3/da active
- 2001-01-25 AR ARP010100326A patent/AR029464A1/es unknown
- 2001-10-03 US US09/972,702 patent/US6416765B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520822A5 (https=) | ||
| JP2003519666A5 (https=) | ||
| JP2003530320A5 (https=) | ||
| Lin et al. | Evidence for histaminergic arousal mechanisms in the hypothalamus of cat | |
| Bigat et al. | Does dexamethasone improve the quality of intravenous regional anesthesia and analgesia? A randomized, controlled clinical study | |
| Suputtitada et al. | The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity | |
| Owen et al. | Analgesia from morphine and ketamine: a comparison of infusions of morphine and ketamine for postoperative analgesia | |
| Clark et al. | Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient | |
| Harrison et al. | Effect of ilioinguinal and iliohypogastric nerve block and wound infiltration with 0.5% bupivacaine on postoperative pain after hernia repair | |
| Song et al. | Antiemetic activity of propofol after sevoflurane and desflurane anesthesia for outpatient laparoscopic cholecystectomy | |
| US20040214849A1 (en) | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic | |
| IL208184A0 (en) | Glp-1, and methods for treating diabetes | |
| US20010014685A1 (en) | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction | |
| Geze et al. | Comparison of local anaesthetic mixtures with tramadol or fentanyl for axillary plexus block in orthopaedic upper extremity surgery | |
| Grélot et al. | Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist | |
| Osgood et al. | Management of burn pain in children | |
| Wang et al. | Axillary brachial plexus block with patient controlled analgesia for complex regional pain syndrome type I: a case report | |
| JP2002530353A5 (https=) | ||
| JPS63275523A (ja) | ヒト成長ホルモンを用いる中毒個体の治療方法 | |
| Zhang et al. | The use of nicardipine for electroconvulsive therapy: a dose-ranging study | |
| Schmidt et al. | Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up | |
| Olsen et al. | Oral glycopyrrolate alleviates drooling in a patient with tongue cancer | |
| WO1996023496B1 (en) | Use of melatonin for treating patients suffering from drug addiction | |
| Kawai et al. | On the conservative treatment of Bell's palsy | |
| Christensen et al. | Analgesic effect of intraarticular morphine. A controlled, randomised and double‐blind study |